A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Reference |
|---|
| "Sarcomas are a relatively rare and heterogeneous group of malignant tumors of principally mesenchymal origin." | ( Elias, AD, 1992) |
| "Stromal sarcomas are extremely rare, occurring much less than any other uterine tumor." | ( Cabrera, JJ; Chirino, R; Falcón, O; Fernández, L; Fernández, P; Jiménez, P; León, L; López, A; Navarro, D; Rivero, JF, 1992) |
| "Pulmonary artery sarcomas are reviewed with emphasis on the diagnosis and management of these usually fatal tumors." | ( Flam, MS; Head, HD; John, MJ; Lipnik, SS; Slater, DL; Stewart, RD, 1992) |
| "Alveolar soft part sarcoma is primarily treated by surgery, and reports of effective chemotherapy have been infrequent." | ( Kanamori, M; Maeda, A; Makiyama, N; Matsui, H, 1991) |
| "Chordoid sarcoma is a rare neoplasm, with only 13 cases reported." | ( Hitchon, H; Levy, W; Nobler, MP; Wohl, M, 1990) |
| "Synovial sarcoma is regarded as a distinctive soft tissue tumor with variable epithelial-like differentiation." | ( Fisher, C, 1986) |
| "Alveolar soft part sarcoma is a rare soft tissue tumor arising in extremities." | ( Kikuchi, K; Masuda, H; Ogata, T; Takagi, K; Tanaka, S, 1988) |
| "Soft tissue sarcomas are uncommon malignancies, less than 10% of which arise on the distal upper extremities." | ( Okunieff, P; Proppe, KH; Suit, HD, 1986) |
| "Soft tissue sarcomas are rare tumors." | ( Lucas, P; Spielmann, M, 1985) |
| "Epithelioid sarcoma is a rare and misleading lesion." | ( Archer, IA; Brown, RB; Fitton, JM, 1984) |
| "Certain sarcomas are known to accumulate high Z elements." | ( Cashwell, RJ; Kan, WC; Lange, TA; Moran, PR; Paliwal, BR; Wiley, AL; Wirtanen, GW, 1980) |
| "Primary myocardial sarcomas are rare." | ( Bidula, LP; Charkes, ND; Denenberg, BS; Malmud, LS; Maurer, AH; Spann, JF, 1983) |
| "Epithelioid sarcoma is a malignant lesion, first described by Enzinger in 1970." | ( Rajan, S; Skau, T, 1983) |
| "Chordoid sarcoma is a rare, distinctive neoplasm that usually occurs in the soft tissue of the extremities." | ( Berson, SD; Jacobs, GH; Jacobson, JN; Rippey, JJ; Skikne, MI, 1982) |
| "Epithelioid sarcoma is a rare and deceptive lesion, often confused both clinically and on histopathological examination with other malignant processes." | ( Erdmann, MW; Quaba, AA; Sommerlad, BC, 1995) |
| "Epithelioid sarcoma is a rare and aggressive malignancy commonly occurring in the tendon sheaths of the distal extremities of young adults." | ( Freeman, JL; Heathcote, JG; Hurwitz, JJ; Rootman, J; White, VA, 1994) |
| "Soft tissue sarcomas are generally resistant to most chemotherapeutic agents, and individuals with advanced disease have a poor prognosis." | ( Balcerzak, SP; Buys, SS; Metch, B; Neefe, JR; Stuckey, WJ, 1994) |
| "Epithelioid sarcoma is a highly malignant soft tissue tumour that is refractory to conventional chemotherapy and irradiation." | ( Dienst, M; Engers, R; Friebe, U; Gabbert, HE; Gerharz, CD; Heymer, T; Moll, R; Pohl, A; Ramp, U; van Roy, F, 1996) |
| "Epithelioid sarcoma is a rare tumor mainly arising in the extremities." | ( Christmann, D; Farcy, JP; Gnassia, JP; Lang, G; Pierchon, F; Steib, JP, 1996) |
| "Osteosarcoma is a clinically heterogeneous disease which continues to resist biologic diagnosis, classification, or staging." | ( Womer, RB, 1996) |
| "Carcinosarcoma is a rare neoplasm that displays morphological features of both an adenocarcinoma and a sarcoma." | ( Castellaneta, A; Gentile, R, 1997) |
| "Epithelioid sarcoma is a malignant soft tissue tumor characterized by its propensity to occur in the distal extremities as a nodular lesion and its slow and asymptomatic growth." | ( Gloor, F; Hardmeier, T; Jungi, F; Schmid, U; Segmüller, G; Sennwald, G, 1983) |
| "Uterine sarcomas are rare tumors which account for 1% of all genital tract malignancies." | ( Erman, O; Simşek, T; Trak, B; Uner, M; Zorlu, GC, 1998) |
| "Soft tissue sarcomas are relatively rare tumors with an aggressive natural history associated with a high propensity for local recurrence following conservative surgery." | ( Badhwar, R; Chaudhary, AJ; Laskar, S, 1998) |
| "One dog with liposarcoma is experiencing a long-term (>12 months) stabilization of disease on PTX." | ( Bohling, CA; Forrest, LJ; Hershey, AE; Imondi, AR; Kurzman, ID; Placke, ME; Stonerook, M; Vail, DM, 1999) |
| "Neurogenic sarcomas are incurable, common malignant human peripheral nerve tumors subject to local recurrence and systemic metastasis." | ( Angelov, L; Guha, A; McMahon, G; Roncari, L; Salhia, B, 1999) |
| "Epithelioid sarcoma is an uncommon malignant tumor, often misdiagnosed by surgeons and pathologists." | ( Alapetite, C; Anract, P; Carlioz, A; Chatelain, D; de Pinieux, G; Ouaknine, M; Tomeno, B, 1999) |
| "Epithelioid sarcoma is a highly malignant soft tissue tumor that is largely resistant to conventional chemotherapy and radiotherapy." | ( Gabbert, HE; Gerharz, CD; Knopf, C; Reinecke, P; Schmitz, M; Schneider, EM, 2000) |
| "Epithelioid sarcoma is an uncommon tumor of uncertain histogenesis that typically arises in the extremities of young adults." | ( Billings, SD; Hood, AF, 2000) |
| "Sarcomas are radioresistant tumors, the only curative therapy being radical surgical resection." | ( Archimandritis, S; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Karkavitsas, NN; Koukouraki, S; Koukourakis, MI; Velidaki, A, 2000) |
| "Synovial sarcoma is a mesenchymal neoplasm of unknown histogenesis that shows various degrees of epithelial differentiation." | ( Lasota, J; Limon, J; Miettinen, M; Niezabitowski, A, 2000) |
| "Epithelioid sarcoma is a distinctive, rare soft tissue sarcoma that typically involves the distal extremities in young adults, and shows epithelioid morphology and immunohistochemical markers of epithelial differentiation." | ( Knuutila, S; Lushnikova, T; Miettinen, M, 2000) |
| "Epithelioid sarcoma is a rare soft tissue tumor that, due to its clinically unspecific features, is frequently mistaken for other benign and malignant entities." | ( Dissemond, J; Goos, M; Wagner, SN, 2002) |
| "Epithelioid sarcoma is an aggressive soft tissue sarcoma with a varied clinical presentation, growth pattern, MR signal characteristics and histologic picture." | ( Fletcher, BD; Gupta, M; Hanna, SL; Hewan-Lowe, K; Jenkins, JJ; Kaste, S; Monson, D; Spence, JV, 2002) |
| "Sarcomas are a heterogeneous group of tumors comprising approximately 1% of all malignancies." | ( Alavi, A; Chiang, SB; Johnson, GR; Khan, J; Zhuang, H, 2003) |
| "Epithelioid sarcomas are uncommon, aggressive tumours with a propensity for locoregional recurrence." | ( Chaudhuri, A; Harris, MD, 2003) |
| "Epithelioid sarcoma is a rare mesenchymal neoplasm." | ( Choi, JH; Jee, KJ; Koh, JK; Lee, DP; Lee, MW; Moon, KC; Ro, JY, 2004) |
| "Soft-tissue sarcomas are mesenchymal tumors that respond poorly to systemic chemotherapy." | ( Berlinghoff, S; Fruehauf, S; Hengge, UR; Laufs, S; Veldwijk, MR; Wenz, F; Zeller, WJ, 2004) |
| "Sarcomas are rare but aggressive malignant tumors associated with high mortality, for which the efficacy of standard therapies remains limited." | ( Ayyoub, M; Hesdorffer, CS; Hesdorffer, M; Hibshoosh, H; Keohan, ML; Mansukhani, M; Memeo, L; Metthez, G; Taub, RN; Valmori, D, 2004) |
| "Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal tissues." | ( Fahn, W; Issels, RD, 2004) |
| "Epithelioid sarcoma is a distinctive, aggressive soft tissue tumor typically presenting as a subcutaneous or deep dermal mass in the distal extremities of young adults." | ( Bergfeld, WF; Fisher, C; Goldblum, JR; Hartke, M; Hicks, D; Lin, L; Montgomery, E; Sigel, JE; Tubbs, R; Xu, B, 2005) |
| "Endometrial stromal sarcoma is a rare malignant uterine tumor." | ( Abadie-Lacourtoisie, S; Catala, L; Descamps, P; Lortholary, A; Morand, C; Paillocher, N; Verriele, V, 2005) |
| "Sarcomas are one of the most refractory diseases among malignant tumors." | ( Batra, S; He, B; Jablons, DM; Koizumi, K; Lee, AY; Mazieres, J; Mikami, I; Reguart, N; Uematsu, K; Xu, Z; You, L, 2005) |
| "Soft tissue sarcomas are a rare group of neoplasms readily dispersed throughout the body with different histopathologies and different outcomes." | ( Brennan, MF, 2005) |
| "Uterine sarcomas are rare tumors." | ( Fietkau, R; Gerber, B; Klautke, G; Kortmann, B; Reimer, T, 2006) |
| "Sarcomas are a rare malignancy accounting for less than 1% of all cancers diagnosed annually." | ( Okuno, S, 2006) |
| "Histiocytic sarcoma is an exceedingly rare malignant neoplasm composed of cells with a monocyte/macrophage phenotype." | ( Frater, JL; Gardner, LJ; Grosso, LE; Hurley, MY; Kling, CW; Obadiah, JM; Resh, B, 2006) |
| "Although FDC sarcoma is considered a low-grade tumor, the tumor in the present case not only developed at an unusual location with bone metastasis but also involved bone marrow." | ( Admirand, JH; Bueso-Ramos, CE; Ford, RJ; Jiang, L; Moran, C, 2006) |
| "Soft tissue sarcomas are rare cancers of mesenchymal origin." | ( Alberti, L; Blay, JY; Cassier, PA; Dufresne, A; Fayette, J; Ranchere, D; Ray-Coquard, I, 2007) |
| "Uterine sarcomas are rare neoplasms characterized by a high rate of local recurrences and distant metastases." | ( Bamias, A; Bozas, G; Dimopoulos, MA; Gika, D; Kastritis, E; Markaki, S; Papadimitriou, CA; Rodolakis, A; Voulgaris, Z; Zorzou, MP, 2007) |
| "Soft tissue sarcomas are a heterogeneous group of tumours that arise predominantly from the embryonic mesoderm." | ( Awada, A; Gil, T; Kasper, B, 2007) |
| "Epithelioid sarcoma is a rare type of soft tissue sarcomas with a high risk of recurrence both local and distant." | ( Bui Nguyen Binh, M; Bui, BN; Coindre, JM; Duparc, A; Guerder, C; Henriques de Figueiredo, B; Kantor, G; Stoeckle, E, 2007) |
| "Histiocytic sarcoma is an uncommon neoplasm of mature histiocytes with a poor clinical outcome." | ( Chang, CC; Chang, CL; Huang, CH; Huang, SC, 2007) |
| "Metastatic sarcomas are commonly resistant to chemotherapy." | ( Brooks, JS; Goodwin, DG; Haupt, HM; Iwenofu, OH; Lackman, RD; Staddon, AP, 2008) |
| "Odontogenic sarcomas are regarded as low-grade tumors that rarely metastasize." | ( Jundt, G; Reichart, PA, 2008) |
| "Monoblastic sarcoma is a rare disease with poor prognosis." | ( Li, JM; Liao, DY; Lu, WP; Yu, JB; Zuo, Z, 2008) |
| "Soft tissue sarcomas are a heterogeneous group of connective tissue tumors, with more than 50 different subtypes." | ( Thornton, K, 2008) |
| "Epithelioid sarcoma is an uncommon high-grade sarcoma, mostly involving the extremities." | ( Arai, K; Hirahashi, M; Iwamoto, Y; Jono, O; Oya, M; Sakamoto, A, 2008) |
| "Sarcomas are among the most proangiogenic malignancies in preclinical models." | ( Baker, LH; Carr, RA; Demetri, GD; Gordon, GB; Humerickhouse, RA; Knight, RA; Mendelson, D; Qian, J; Rowinsky, EK, 2008) |
| "Sarcoma is not necessarily associated with very high serum total ALP." | ( Davie, MW; Grimer, RJ; Mangham, DC, 2009) |
| "However, sarcomas are heterogeneous and therefore single slice DCE-MRI may not correlate with total tumor necrosis." | ( Blackstein, ME; Bleakney, RR; Kandel, R; Lee, S; Noseworthy, M; Toms, AP; White, LM; Wunder, J, 2009) |
| "Gastric sarcoma is a rare form of malignancy constituting approximately 0." | ( Gamble, B; Ho, L; Meka, M, 2009) |
| "Soft tissue sarcomas are rare tumors." | ( Blay, JY; Bui, B; Cassier, P; Dufresne, A; Le Cesne, A; Vanel, D, 2009) |
| "Sarcomas are a heterogeneous group of >50 subtypes of neoplasm." | ( Landa, J; Schwartz, LH, 2009) |
| "Sarcomas are the mesenchymal-derived malignant tumors of connective tissues (e." | ( Matushansky, I; Mills, J; Siddiqi, S, 2010) |
| "Soft tissue sarcoma is a malignant connective tissue tumor that may arise anywhere in the body and from diverse mesenchymal elements." | ( Patel, S; Schuetze, SM, 2009) |
| "Soft tissue sarcomas are a highly heterogeneous group of malignancies that arise from mesenchymal tissues." | ( Choe, JG; Kang, CH; Kim, CH; Noh, W; Park, EK; Park, JH, 2009) |
| "Uterine sarcomas are very rare malignancies with no approved chemotherapy protocols." | ( Denk, H; Hrzenjak, A; Kremser, ML; Moinfar, F; Petru, E; Strohmeier, B; Zatloukal, K, 2010) |
| "Sarcomas are uncommon malignancies that represent more than 50 different tumor types." | ( Garralda Cabanas, E; Hitt, R; Homet Moreno, B, 2010) |
| "Vulvar epithelioid sarcoma is a rare, undifferentiated soft-tissue sarcoma, with a high rate of local relapse, regional nodal spread and distant metastases." | ( Bai, P; Li, XG; Sun, L; Wu, LY; Zhang, HT, 2010) |
| "Sarcomas are a diverse group of malignancies originating in the connective tissue." | ( Ceyssens, S; Stroobants, S, 2011) |
| "Epithelioid sarcoma is a rare soft tissue sarcoma subtype." | ( Al-Muderis, O; Constantinidou, A; Fisher, C; Jones, RL; Judson, IR; Olmos, D; Scurr, M; Thway, K, 2012) |
| "Breast stromal sarcoma is very rare, accounting for less than 1% of mammary neoplasms, and the treatment strategy is not well established, especially regarding chemotherapy." | ( Inoue, K; Iwase, H; Kuriwaki, K; Sueta, A; Yamamoto, Y, 2011) |
| "Sarcomas are rare heterogeneous malignancies of mesenchymal origin relatively common during childhood." | ( D'Onofrio, L; Frezza, AM; Napolitano, A; Santini, D; Silletta, M; Tonini, G; Venditti, O; Vincenzi, B, 2011) |
| "Soft tissue sarcomas are rare tumours in adults and therefore require a multidisciplinary approach for optimal management." | ( Movva, S; Verschraegen, C, 2011) |
| "Clear cell sarcoma is a unique soft tissue tumor with distinct microscopic features that include a nested or fascicular pattern of spindle cells accompanied by larger wreath-like giant cells scattered throughout." | ( Bacchi, CE; Falconieri, G; Luzar, B, 2012) |
| "Retroperitoneal sarcomas are rare and aggressive tumors with a negative prognosis as there is currently no satisfactory treatment for them." | ( Lazar, AM, 2012) |
| "Uterine sarcomas are rare and comprise only 3% of all uterine cancers." | ( Reichardt, P, 2012) |
| "Epithelioid sarcoma is a rare soft tissue neoplasm that usually arises in the distal extremities of young adults." | ( Brenca, M; Dei Tos, AP; Giuliano, A; Lorenzetto, E; Maestro, R; Modena, P; Piccinin, E; Piccinin, S; Rossi, FM; Rossi, S, 2013) |
| "Soft tissue sarcomas are a heterogeneous group of malignant tumors." | ( Cheng, EY; Clohisy, DR; Manivel, JC; O'Donnell, PW, 2014) |
| "Primary cardiac sarcomas are rare and carry a poor prognosis." | ( Bartz, PJ; Collins, CL; Lal, DR; Segura, AD; Tower, RL; Woods, RK, 2014) |
| "Soft-tissue sarcomas are a heterogeneous group of tumors arising from connective tissue." | ( Barretina, J; Chitalia, R; Dodd, L; Dodd, RD; Eward, WC; Kirsch, DG; Ma, Y; Mito, JK; Sachdeva, M, 2013) |
| "Soft-tissue sarcomas are rare tumours of mesenchymal origin." | ( , 2013) |
| "Soft-tissue sarcomas are a group of malignancies of mesenchymal origin, which typically have a dismal prognosis if they reach the metastatic stage." | ( Giovannoni, L; Green, AJ; Hemmerle, T; Meyer, T; Neri, D; Probst, P, 2013) |
| "Synovial sarcoma is part of soft tissue sarcomas, an uncommon group of malignant tumors of mesenchymal origin." | ( Ferrari, S; Paioli, A; Palmerini, E, 2014) |
| "Soft tissue sarcomas are a heterogenous group of malignancies with relatively high mortality rates." | ( Elias, A; Gajdos, C; Lopez, JP, 2014) |
| "Sarcomas are a group of rare solid tumours arising from mesenchymal or connective tissue." | ( Cornillie, J; Hompes, D; Li, H; Schöffski, P; Wozniak, A, 2014) |
| "Sarcoma is a rare form of cancer that differs from the much more common carcinomas because it occurs in a distinct type of tissue." | ( Chiu, HW; Foo, NP; Guo, HR; Hsu, YH; Lin, YF; Tseng, YC; Wang, YJ, 2015) |
| "Angiosarcoma is a rare subtype of soft tissue sarcoma (STS)." | ( Litière, S; Natukunda, A; van der Graaf, WT; Wardelmann, E; Woll, PJ; Young, RJ, 2014) |
| "Sarcomas are a rare family of heterogeneous tumors of mesenchymal origin characterized by their bad prognosis." | ( García del Muro, X; Martin-Liberal, J; Tirado, OM, 2015) |
| "Soft tissue sarcomas are a group of rare tumors derived from mesenchymal tissue, accounting for about 1% of adult cancers." | ( Jones, RL; Loggers, ET; Petek, BJ; Pollack, SM, 2015) |
| "Meningeal sarcomas are rare, highly aggressive malignant tumors, predominately affecting the pediatric population and have a poor prognosis in spite of treatment." | ( Bernal García, LM; Cabezudo Artero, JM; López Macías, M; Marcelo Zamorano, MB; Royano Sánchez, M, 2015) |
| "If a soft-tissue sarcoma is present, radical oncological resection with sufficiently wide surgical margins is the most important cornerstone of curative therapy." | ( Germann, G; Mehling, IM; Moll, W; Sauerbier, M; Schloßhauer, T, 2015) |
| "Musculoskeletal sarcomas are aggressive malignancies of bone and soft tissues often affecting children and adolescents." | ( Avnet, S; Baldini, N; Di Pompo, G; Lattanzi, G; Mai, A; Rotili, D; Salerno, M; Valente, S; Zwergel, C, 2015) |
| "Epithelioid sarcoma is a rare mesenchymal neoplasm, with an as yet unidentified cell of origin." | ( Dodd, LG; Pendse, AA, 2015) |
| "Uterine sarcomas are rare and aggressive gynecologic tumors with a poor prognosis because of recurrence and metastasis." | ( Hosoda, H; Imamichi, Y; Ishikane, S; Kangawa, K; Kawabe, S; Kiyono, Y; Martinez, ME; Miura, K; Miyamoto, K; Mizutani, T; Yoshida, Y, 2015) |
| "Sarcomas are rare cancers and the current treatments in inoperable or metastatic disease have not been shown to prolong survival." | ( Nair, JS; Schwartz, GK, 2015) |
| "OBJECT Primary CNS sarcomas are very rare pediatric tumors with no defined standard of care." | ( Bartels, U; Bouffet, E; Hader, W; Hawkins, C; Lafay-Cousin, L; Laperriere, N; Laughlin, S; Lindzon, G; Nordal, R; Taylor, MD, 2016) |
| "Its indication in sarcomas is still controversial." | ( Bochev, P; Chaushev, B; Dancheva, Z; Klisarova, A; Yordanova, T, 2016) |
| "Uterine sarcomas are a group of mesenchymal tumours comprising several histologies." | ( Benson, C; Blay, JY; Chawla, S; Dewji, MR; Gil, T; Judson, I; Le Cesne, A; Litière, S; Marréaud, S; Papai, Z; Piperno-Neumann, S; Ray-Coquard, I; Schöffski, P; Sleijfer, S; van der Graaf, WTA, 2016) |
| "Cutaneous sarcomas are primarily treated with extensive surgery, and occasionally require adjuvant radiation therapy following complete wound healing." | ( Jungmann, J; Mohammad, F; Müller, CS; Pföhler, C; Rübe, C; Vogt, T, 2016) |
| "Soft tissue sarcomas are rare malignant tumors with a great variety of histological types and different response to multimodality treatment." | ( Agrafiotis, AC; Grosdidier, G; Prieto, M; Rios, M; Siat, J; Verhaeghe, JL, 2016) |
| "Sarcomas are malignant tumors accounting for a high percentage of cancer morbidity and mortality in children and young adults." | ( Carnero, A; Felipe-Abrio, I; Ferrer, I; Garcia-Heredia, JM; Martin-Broto, J; Peinado-Serrano, J; Perez, M; Saez, C; Tous, C, 2016) |
| "Soft-tissue sarcoma is one of the few specific tumors thought to be caused by polychlorinated dibenzo-p-dioxins and dibenzofurans (PCDD/Fs) and specifically TCDD." | ( Airaksinen, R; Kiviranta, H; Pekkanen, J; Tukiainen, E; Tuomisto, J; Tuomisto, JT, 2017) |
| "Epithelioid sarcoma is a heterogeneous tumor with 2 subtypes, classic and proximal." | ( Bhattacharyya, R; Chatterjee, U; Ghosh, R; Saha, K, 2017) |
| "Radiation-related sarcoma is a rare but serious complication for patients after receiving radiation therapy initially for their primary malignancy." | ( Chang, CP; Huang, WS; Lee, TH; Wu, YH, 2017) |
| "Soft tissue sarcomas are a histologically heterogeneous group of rare mesenchymal cancers for which treatment options leading to increased overall survival have not improved in over two decades." | ( Allen, BG; Bradley, MD; Buettner, GR; Mapuskar, KA; Milhem, M; Monga, V; Schoenfeld, JD; Sibenaller, ZA; Spitz, DR; Wagner, BA, 2018) |
| "Sarcomas are rare, heterogeneous tumors for which prognosis remains dismal in patients with advanced disease." | ( Bupathi, M; Chen, JL; Hays, JL, 2017) |
| "When soft tissue sarcomas are treated with neoadjuvant chemotherapy, the number of cycles of chemotherapy is usually dependent on the tumor's initial response." | ( Davidson, DJ; Elojeimy, S; Favinger, JL; Ha, AS; Hippe, DS; Lindberg, AW; Roth, ES, 2018) |
| "Soft tissue sarcomas are a group of rare tumors of mesenchymal origin, and account for less than 1% of all cancers." | ( Ganjoo, KN; Kolla, KR; Seetharam, M, 2018) |
| "Uterine sarcoma is a rare gynecologic cancer, and chemotherapy is one type of cancer treatment." | ( Chang, CC; Chiang, W; Hsia, SM; Huang, LH, 2018) |
| "Sarcomas are still unsolved therapeutic challenges." | ( Andrique, C; Chibon, F; Cissé, MY; Cohen-Solal, M; Ea, HK; Haÿ, E; Linares, LK; Merle, C; Modrowski, D; Morardet, L; Provot, S, 2018) |
| "Extraskeletal osteosarcoma is a rare, high-grade soft tissue malignancy, accounting for approximately 1% of all soft tissue sarcomas." | ( Goni, V; Kumar, R; Mittal, BR; Parihar, AS; Sood, A; Vadi, SK, 2018) |
| "Sarcomas are rare and heterogeneous cancer variants of mesenchymal origin." | ( De, AK; Misra, SK; Ostadhossein, F; Pan, D; Rund, L; Schook, L; Singh, K; Ye, M, 2018) |
| "Prostatic stromal sarcoma is quite aggressive and can spread to lung, liver, bone, and other organs." | ( Ding, C; Lai, R, 2019) |
| "However, advanced sarcomas are often resistant, thus stressing the need for new therapies aimed to overcome this resistance." | ( Allonca, E; Alvarez-Fernandez, C; Astudillo, A; Braña, A; Costales, P; Estupiñan, O; Fernandez-Garcia, MT; Fernandez-Nevado, L; Hermosilla, MA; Menendez, ST; Moris, F; Oro, P; Perez-Escuredo, J; Rey, V; Rodriguez, A; Rodriguez, R; Santos, L; Tornin, J, 2019) |
| "Sarcoma is a rare tumor with more than 50 histologic subtypes." | ( Fangxing, W; Jiaqiang, W; Qiqing, C; Weitao, Y, 2019) |
| "Musculoskeletal sarcomas are rare and aggressive human malignancies affecting bones and soft tissues with severe consequences, in terms of both morbidity and mortality." | ( Avnet, S; Baldini, N; Costa, F; Kusuzaki, K; Martano, M; Morello, E; Sammartano, F, 2019) |
| "Sarcoma is a rare and recalcitrant malignancy." | ( Dry, SM; Hayashi, K; Higuchi, T; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kimura, H; Kiyuna, T; Li, Y; Miwa, S; Miyake, K; Miyake, M; Murakami, T; Nelson, SD; Oshiro, H; Singh, SR; Tsuchiya, H; Yamamoto, N, 2020) |
| "Malignant cutaneous sarcomas are generally incurable and ultimately impair patients' quality of life." | ( Hoshi, M; Iwai, T; Nakamura, H; Oebisu, N, 2020) |
| "Soft tissue sarcomas are a heterogeneous and rare group of cancers with a short median overall survival despite the chemotherapy." | ( Araz, M; Artaç, M; Eryılmaz, MK; Kaplan, MA; Karaağaç, M; Sezgin, Y, 2020) |
| "Sarcomas are rare and heterogeneous malignant tumors relatively resistant to radio- and chemotherapy." | ( Chiarugi, P; Leo, A; Pietrovito, L; Taddei, ML, 2020) |
| "Sarcomas are heterogeneous malignant mesenchymal neoplasms with limited sensitivity to immunotherapy." | ( Adam, J; Bessede, A; Bodet, D; Bortolotto, D; Cerf, L; Chaibi, A; Italiano, A; Larmonier, CB; Le Loarer, F; Nafia, I; Rey, C; Savina, A; Toulmonde, M; Velasco, V, 2020) |
| "Epithelioid sarcoma is an extremely rare and aggressive tumor affecting young adults that is characterized by loss of INI1 expression." | ( Italiano, A, 2020) |
| "Soft tissue sarcomas are associated with a poor prognosis and low chemotherapeutic efficiency." | ( Aydın, D; Beşiroğlu, M; Bilici, M; Dane, F; Doğu, GG; Hacıoğlu, B; Kaplan, NB; Karaca, M; Koca, S; Oruç, Z; Özçelik, M, 2021) |
| "Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease." | ( Blay, JY; Ray-Coquard, I; Schöffski, P, 2020) |
| "Soft-tissue sarcomas are a rare group of malignant tumors that usually are treated with surgical excision and radiation therapy, but recently, pazopanib, an oral tyrosine kinase inhibitor, has been used in patients with metastases who do not respond to standard chemotherapy regimens." | ( Akaike, K; Hayashi, T; Ikegami, M; Kaneko, K; Kato, S; Kim, Y; Kohsaka, S; Kojima, S; Kurihara, T; Mano, H; Mizuno, S; Okubo, T; Saito, T; Sano, K; Sasa, K; Suehara, Y; Ueno, T; Yamaguchi, S, 2020) |
| "Soft tissue sarcomas are a group of tumors derived from the mesenchymal origin." | ( Al-Rohil, RN; Bentley, RC; Cardona, DM; Feng, X; Jour, G; Shen, G; Underwood, CIM, 2020) |
| "Uterine sarcomas are very rare tumours with different histotypes, molecular features and clinical outcomes; therefore, it is difficult to carry out prospective clinical trials, and this often results in heterogeneous management of patients in the clinical practice." | ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020) |
| "Early-stage uterine sarcomas are managed by hysterectomy + bilateral salpingo-oophorectomy according to menopausal status and histology; lymphadenectomy is not indicated in patients without bulky nodes, and morcellation must be avoided." | ( Aristei, C; Biondetti, PR; Cananzi, FCM; Casali, P; Ciccarone, F; Colombo, N; Comandone, A; Corvo', R; De Iaco, P; Dei Tos, AP; Donato, V; Ferrandina, G; Fiore, M; Gadducci, A; Gronchi, A; Guerriero, S; Infante, A; Lorusso, D; Odicino, F; Pirronti, T; Quagliuolo, V; Sanfilippo, R; Scambia, G; Testa, AC; Zannoni, GF, 2020) |
| "Epithelioid sarcoma is a rare and aggressive soft-tissue sarcoma subtype." | ( Agarwal, S; Agulnik, M; Attia, S; Chen, TW; Chugh, R; Cote, GM; Davis, LE; Demetri, GD; Dileo, P; Gounder, M; Gupta, A; Italiano, A; Jahan, T; Jones, RL; Lingaraj, T; Loggers, ET; Mir, O; Pressey, JG; Rajarethinam, A; Ratan, R; Schöffski, P; Sierra, L; Stacchiotti, S; Van Tine, BA; Villalobos, VM, 2020) |
| "Sarcomas are uncommon malignancies." | ( Alameh, IA; Assi, HI; Charafeddine, M; Farhat, F; Halim, NA; Karak, FE; Khoury, J; Nakib, CE; Sayed, RE; Zerdan, MB, 2021) |
| "Promyelocytic sarcoma is an uncommon solid tumor made up of myeloblasts." | ( Bonnefoy, PB; Cornillon, J; Flandrin, P; Jacquet-Francillon, N; Prevot, N; Rigollet, L; Tavernier, E, 2021) |
| "Soft tissue sarcomas are rare tumors that represent a major challenge due to varying clinical presentations and often interdisciplinary treatment concepts." | ( Pink, D; Reichardt, P, 2021) |
| "Mesenchymal sarcomas are tumors that originate from mesenchymal tissue." | ( Chen, W; Hou, Y; Jiang, D; Luan, L; Wang, H; Zhou, Y, 2021) |
| "Ewing's sarcoma is a very rare type of cancerous tumor that grows in bones or the soft tissue around the bones, such as cartilage or the nerves." | ( Afridi, HI; Baig, JA; Chanihoon, GQ; Kazi, TG; Talpur, FN, 2021) |
| "Pleomorphic dermal sarcoma is a rare neoplasm of mesenchymal origin that most commonly affects the head." | ( Baxter, EM; Chengot, P; Parmar, JD; Patel, KB; Williams, JV, 2022) |
| "Local control in sarcoma is rarely achieved with exclusive radiotherapy (RT)." | ( Blanc, E; Blay, JY; Cassier, PA; Largo, AC; Montané, L; Penel, N; Pérol, D; Sargos, P; Sunyach, MP, 2022) |
| "However, because sarcoma is very rare, there is little evidence regarding the management of elderly patients with sarcoma." | ( Ozaki, T; Tanaka, K, 2022) |
| "Sarcomas are rare diagnoses but are seen with relative frequency in adolescents and young adults and thus can present in pregnancy." | ( Agulnik, M; Davis, LE; Godbole, S; Hirbe, AC; Livingston, JA; Miller, D; Park, Y; Parkes, A; Posey, K; Robinson, SI; Skubitz, K; Van Tine, BA, 2022) |
| "Spindle cell sarcoma is a connective tissue tumor usually involving bone or muscle." | ( Agrawal, A; Bakshi, G; Joshi, A; Kale, SA; Menon, S; Murthy, V; Prakash, G; Purandare, N; Puranik, A; Rangarajan, V; Shah, S, 2022) |
| "Primary epithelioid sarcoma is an extremely rare malignancy of the scalp." | ( Ho, CL; Mirpuri, TM; Zhang, Y, 2021) |
| "CIC-rearranged sarcomas are newly defined undifferentiated soft tissue tumors with CIC-associated fusions, and dismal prognosis." | ( Bagatell, R; Cao, K; Chen, J; Cole, KA; Fan, Z; Fu, W; Kreiger, PA; Li, MM; Long, A; Luo, M; Pagliaroli, L; Ruiz, J; Santi, M; Schubert, J; Storm, PB; Surrey, LF; Viaene, AN; Wertheim, GB; Wu, J; Xu, F; Zhong, Y, 2022) |
| "Bone sarcomas are devastating primary bone cancers that mostly affect children, young adults, and the elderly." | ( Blair, HJ; Chan, CD; Knight, JC; Luli, S; Pringle, TA; Rankin, KS, 2022) |
| "Sarcoma is a rare and heterogeneous class of mesenchymal malignancies with poor prognosis." | ( Liu, M; Lu, X; Que, Y; Yang, J; Zhang, X, 2022) |
| "Most sarcomas are highly aggressive, and cause necrosis and hemorrhage." | ( Fujii, T; Fujimoto, K; Itami, H; Maebou, K; Matsuoka, M; Miyake, M; Morita, K; Nitta, Y; Ohbayashi, C; Okada, F; Sasaki, S; Sawabata, N; Sugimoto, S; Takeda, M; Terada, C; Uchiyama, T, 2022) |
| "Sarcomas are a rare group of tumors with many subtypes, conventionally classified into soft-tissue sarcomas and bone sarcomas." | ( Blay, JY; Duffaud, F; George, S; Maki, RG; Penel, N, 2022) |
| "Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Pancreatic Ewing's sarcoma is not reported commonly, with inconsistent clinical manifestations." | ( Chan, WT; Hou, JY; Jiang, CB; Lee, HC; Liu, HC; Liu, YC; Sheu, JC; Wu, PS; Yeh, TC; Yeung, CY, 2022) |
| "Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
| "Thoracic sarcomas are rare malignancies, with limited data for unresectable/advanced scenarios." | ( Alatorre-Alexander, JA; Carrasco-CaraChards, S; Cruz-Zermeño, M; de Jesús Rodríguez-Zea, I; Godina-Flores, A; Green-Renner, D; Guzmán-Casta, J; Guzmán-Huesca, J; Imaz-Olguin, V; Juarez-Vignon Whaley, JJ; Martínez-Barrera, LM; Riera-Sala, R; Rodriguez-Cid, JR; Sánchez-Domínguez, G; Sánchez-Ríos, CP; Santillán-Doherty, PJ; Seidman-Sorsby, A; Sosa-Sánchez, R, 2023) |
| "Data on sarcomas are limited, and insufficient on retroperitoneal sarcoma (RPS)." | ( Barisella, M; Callegaro, D; Fiore, M; Gronchi, A; Ljevar, S; Miceli, R; Morelli, D; Pasquali, S; Sanfilippo, R; Sangalli, C, 2023) |
| "Data on sarcomas are limited, and insufficient on retroperitoneal sarcoma (RPS)." | ( Barisella, M; Callegaro, D; Fiore, M; Gronchi, A; Ljevar, S; Miceli, R; Morelli, D; Pasquali, S; Sanfilippo, R; Sangalli, C, 2023) |
| "Angiosarcomas are a rare subtype representing 1-2% of soft tissue sarcomas." | ( Bay, JO; El-Ghazzi, N, 2023) |
| "Irradiation-induced sarcomas are the development of sarcoma different from the primary tumor after a latent period of ≥3 years or more in the radiotherapy field." | ( Batur, A; Isik Bedir, S; Karabagli, H; Karabagli, P; Koksal, Y; Ozturk, M; Yavas, G, 2023) |
| "Intimal sarcoma is an extremely rare, life-threatening malignant neoplasm." | ( Ando, RM; Hirakawa, A; Ichikawa, H; Kohsaka, S; Kojima, Y; Koyama, T; Matsui, N; Nakamura, K; Okuma, HS; Sadachi, R; Shimizu, T; Shimoi, T; Sudo, K; Ueno, T; Yamamoto, N; Yanagaki, M; Yonemori, K; Yoshida, A, 2023) |
| Excerpt | Reference |
|---|
| "One pretreatment sarcoma line, STSAR90, was 6-fold less sensitive to doxorubicin than was a normal fibroblast line, AG1522." | ( Beckett, MA; Cohen, MB; Murray, JL; Safa, AR; Samuels, BL; Sinha, BK; Townsend, AJ; Weichselbaum, RR, 1991) |
| "In the treatment of osteosarcoma and Ewing's sarcoma, ifosfamide has been identified as an effective drug." | ( Dirix, LY; Van Oosterom, AT, 1990) |
| "Activity in previously untreated sarcomas should be further evaluated in a randomized phase III study against a standard DOX-containing combination." | ( Antman, KH; Elias, AD, 1986) |
| "Human monocytes kill Actinomycin D-treated WEHI 164 sarcoma cells in a 6 h 51Cr release assay (drug dependent cellular cytotoxicity, DDCC)." | ( Bersani, L; Colotta, F; Ghezzi, P; Mantovani, A, 1985) |
| "Patients with documented untreated soft tissue sarcoma of the lower limb are given continuous intra-arterial regional infusion with adriamycin consecutively for 8 days up to a dose of 100 mg/m2." | ( Andreola, S; Audisio, RA; Azzarelli, A; Bonfanti, G; Gennari, L; Quagliuolo, V, 1983) |
| "The groups active in the treatment of osteosarcomas and Ewing's sarcomas should be encouraged to investigate the new active drugs in the relapsing patients." | ( van Oosterom, AT; Verweij, J, 1995) |
| "We have used ifosfamide to treat patients with sarcomas in four completed single-agent protocols and one pilot study since 1985." | ( Benjamin, RS; Legha, SS; Nicaise, C; Patel, SR, 1993) |
| "We therefore compared 30 patients treated for Ewing sarcoma between 1978 and 1991 with 26 soft tissue sarcoma (STS) patients treated with similar chemotherapy over the same period of time." | ( Chan, KW; Fryer, C; Kakadekar, AP; Popov, R; Pritchard, S; Rogers, PC; Sandor, GG, 1997) |
| "Effective treatments for sarcoma spread to peritoneal surfaces would benefit this small but symptomatic group of patients." | ( Sugarbaker, PH; Zanarini, D, 1997) |
| "Ifosfamide has important activity in pretreated soft tissue sarcomas (STS), and recent data support a clinically significant dose-response relationship for this agent." | ( Antimi, M; Gatti, C; Palmeri, S; Palumbo, R; Raffo, P; Toma, S; Villani, G, 1997) |
| "Over the past 6 years, 28 patients were treated for sarcomas of the extremity in which soft-tissue reconstruction was needed for complete limb salvage." | ( Carras, AJ; O'Keefe, RJ; Rosier, RN; Serletti, JM, 1998) |
| "Thirty-three patients with untreated sarcomas (soft tissue: n = 20; gynecological: n = 11; bone: n = 2) were treated with ifosfamide 12 g/m2 by continuous i." | ( Bacchi, M; Bressoud, A; Cerny, T; Hermann, R; Leyvraz, S; Lissoni, A; Sessa, C, 1998) |
| "Isolated limb perfusion is used to treat unresectable sarcoma, melanoma, and other select tumors." | ( Berthà, R; Fraser, M; Marentay, P, 1999) |
| "Definitive treatment of sarcoma is surgical resection." | ( Alavi, A; Chiang, SB; Johnson, GR; Khan, J; Zhuang, H, 2003) |
| "In addition, 5FC treatment of bone sarcomas caused a significant reduction in cancer-induced bone destruction (P < 0." | ( Clohisy, DR; Goblirsch, M; Lewis, V; Lynch, C; Mantyh, P; Orchard, P; Pan, W; Ramnaraine, M, 2003) |
| "Thirty-six previously treated soft tissue sarcoma patients from three institutions received ET-743 as a 24-hour continuous intravenous (IV) infusion at a dose of 1,500 microg/m(2) every 3 weeks." | ( Canniff, J; Demetri, GD; Garcia-Carbonero, R; Gomez, J; Goss, G; Guzman, C; Harmon, D; Jimeno, J; Lopez, T; Maki, RG; Manola, J; Matulonis, U; Merriam, P; Puchalski, TA; Quigley, MT; Ryan, DP; Sancho, MA; Seiden, MV; Supko, JG, 2004) |
| "Forty-nine patients with pretreated soft tissue sarcoma (the STS arm) and 18 patients with previously untreated gastrointestinal stromal tumor (the GIST arm) were enrolled onto a 2-arm, multicenter, Phase II study between November 1999 and July 2001." | ( Bover, I; Buesa, JM; Casado, A; Cruz, J; Garcia del Muro, X; Lopez-Pousa, A; Martin, J; Martinez-Trufero, J; Maurel, J; Poveda, A, 2005) |
| "For the targeted treatment of sarcomas, AP23573 has shown promising clinical efficacy and low toxicity profiles in patients." | ( Helman, LJ; Wan, X, 2007) |
| "Patients treated on sarcoma protocols containing ifosfamide as the only potential gonadotoxic agent, were evaluated, assessing pubertal development, menstrual history in the females and semen analysis in males." | ( Crofton, PM; Levitt, G; Williams, D, 2008) |
| "In primary biopsies of 41 HILP-TM-treated sarcomas (37 STSs and 4 BS), MT expression was assessed by an immunoreactive score." | ( Grabellus, F; Jasani, B; Kaiser, GM; Lehmann, N; Schmid, KW; Sheu, SY; Taeger, G; Tötsch, M, 2010) |
| "Ifosfamide is currently used to treat pediatric sarcomas and increasing its dosage may be associated with a better response rate." | ( Casanova, M; Cefalo, G; Favini, F; Ferrari, A; Luksch, R; Massimino, M; Meazza, C; Podda, M, 2010) |
| "Animal experiments: Treatment of AH13r Sarcomas in SD-rats." | ( Fahrig, R; Fahrig, T; Heinrich, JC; Schroeder, M; Tuukkanen, A, 2011) |
| "In the treatment of bone sarcoma, evaluation of chemotherapeutic effects is extremely important." | ( Hayashi, K; Igarashi, K; Kimura, H; Miwa, S; Nishida, H; Ooi, A; Shirai, T; Takeuchi, A; Taki, J; Tanzawa, Y; Tsuchiya, H; Yamamoto, N, 2012) |
| "The potential to treat osteosarcoma by inhibition of Gli2 and the role of the pathway in ovarian fibromas and other connective tissue tumors is also discussed (Nagao et al." | ( Cain, JE; Healy, JM; Kelleher, FC; Thomas, DM; Watkins, DN, 2012) |
| "Current systemic treatment of sarcoma is of limited efficacy and inhibiting FOXM1 represents a potential new strategy." | ( Kelleher, FC; O'Sullivan, H, 2016) |
| "In this heavily pre-treated, advanced sarcoma population, the addition of mTOR inhibition to VEGFRi based therapy resulted in a clinical benefit for a subset of patients." | ( Chen, JL; ElNaggar, AC; Hays, JL, 2016) |
| "For patients with doxorubicin-pretreated soft-tissue sarcoma, regorafenib significantly improved quality-adjusted survival in comparison with a placebo." | ( Basson, L; Berry, V; Bertucci, F; Blay, JY; Bogart, E; Brodowicz, T; Chevreau, C; Clisant-Delaine, S; Decoupigny, E; Italiano, A; Le Cesne, A; Liegl-Antzager, B; Mir, O; Penel, N; Taieb, S; Tresch-Bruneel, E; Wallet, J, 2017) |
| "There is a strong rationale for treating sarcomas with immunotherapy." | ( Adam, J; Bessede, A; Blay, JY; Bompas, E; Chevreau, C; Cousin, S; Ghiringhelli, F; Grellety, T; Italiano, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Pulido, M; Ryckewaert, T; Toulmonde, M, 2018) |
| "Although eribulin is used to treat soft tissue sarcomas (STSs), treatment data for rare subtypes are limited." | ( Asano, N; Endo, M; Kawai, A; Kobayashi, E; Maejima, A; Megumi, Y; Naito, Y; Takahashi, S, 2019) |
| "In this cohort of AYAs treated for sarcoma, 64% of the patients received opioid prescriptions during treatment, and 23% of these patients became new persistent users." | ( Accordino, MK; Beauchemin, MP; Cogan, JC; Hershman, DL; Kahn, JM; Raghunathan, RR; Wright, JD, 2022) |
| "Despite ongoing treatment for sarcoma, 22 weeks after initial PMVT treatment, the wound had fully closed with thick epidermis covering the residual granulating part of the wound site." | ( Dobke, MK, 2023) |